技术进步,FoundationOne CDx和FoundationOne Heme检测出具有高灵敏度和特异性的爱斯坦-巴尔病毒
Julius Honecker1, Dirk Paffenholz1, Julian Jungmann1
1Foundation Medicine GmbH, Penzberg, Germany.
The Journal of molecular diagnostics : JMD
|July 25, 2025
概括
基金会One CDx和Heme测定精确检测瘤中的爱斯坦-巴尔病毒 (EBV),为EBV相关癌症提供了传统方法的可靠替代方案.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 基因组学就是基因组学.
背景情况:
- 精确检测爱斯坦-巴尔病毒 (EBV) 对于诊断和管理与EBV相关的癌症至关重要.
- 像EBER ISH这样的传统方法可能耗时,并且可能会错过某些瘤类型中的EBV存在.
研究的目的:
- 为了验证FoundationOne CDx (F1CDx) 和FoundationOne Heme (F1H) 下一代测序试验用于EBV检测的性能.
- 为了比较这些测试的准确性与已建立的EBER in situ杂交 (ISH) 参考标准.
主要方法:
- 总共分析了413个瘤样本 (胃癌,状细胞癌,扩散大B细胞淋巴瘤).
- 使用下一代测序试验 (F1CDx,F1H) 来检测EBV,结果与EBER ISH相比较.
- 进行了稀释实验,以评估试验线性和动态范围.
主要成果:
- 在F1CDx和F1H测定中,EBV检测的高灵敏度 (94.0%),特异性 (99.1%) 和精度 (98.3%) 均为高.
- 观察到与EBER ISH有很强的一致性 (AUC = 0.97),精度很好 (95.5%) 和可重现性 (CV = 4.7%).
- 在广泛的动态范围中证实了线性,与EBV阳性样本相关的特征性基因组变化.
结论:
- 在单个试验中,F1CDx和F1H提供了一种可靠的并行方法,用于检测EBV以及体质基因组改变.
- 这些测试为传统的ISH提供了有希望的替代方案,可能简化EBV相关恶性瘤的诊断工作流程.
- 该方法提高了 EBV 在瘤中的识别,即使没有初步的临床怀疑,有助于诊断和管理.
相关概念视频
Rapid Identification of Pathogens
MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...
Automated Microbial Diagnostics
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...


